ZUG, Switzerland--(BUSINESS WIRE)--Galderma presented the latest data from its pivotal phase III OLYMPIA 2 trial at the 25 th World Congress of Dermatology (WCD) in Singapore. The results highlight ...

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the first patient enrollment for its phase ...

The first and only treatment for the disabling skin condition prurigo nodularis has been approved by the Food and Drug Administration in a development a D.C. dermatologist calls “huge.” Prurigo ...

Randomized Phase 2 study met its primary and secondary endpoints following 16 weeks of treatment across all dosing groups, reinforcing povorcitinib’s potential role in treating prurigo nodularis (PN) ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The FDA has ...

Prurigo nodularis, a chronic debilitating inflammatory skin disease that causes extreme quality of life disruptions, affects approximately 75,000 adults in the United States, who are most in need of ...

Recommendation is based on data from two pivotal trials showing Dupixent significantly improved itch, skin lesions and health-related quality of life in adults with prurigo nodularis If approved, ...

Dear Dr. Gott: I have been plagued for years by an incurable skin condition I am told is called prurigo nodularis. I have tried a sunlight box and a tanning bed, as well as cortisone injections, ...

A recent review found that new methods of treatment for prurigo nodularis had promising results, including approaches that target interleukin 31 and its receptor. A review published in Dermatology and ...

(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) and Sanofi said Tuesday that the U.S. Food and Drug Administration has accepted for Priority Review the supplemental Biologics License Application or ...

HAMILTON, Bermuda, Nov. 16, 2020 (GLOBE NEWSWIRE) -- KiniksaPharmaceuticals, Ltd. (Nasdaq: KNSA) (“Kiniksa”), a biopharmaceutical company with a pipeline of assets designed to modulate immunological ...